EN DE
Watch Veru Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Veru Inc (VERU) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Veru Inc stock $1.67, price $2.08, that is 19.7% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US92536C1036

VI Veru Inc logo Thin data Nov 17, 2026

Veru Inc

VERU · US

Expensive (fair value 20% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +18% vs. a year ago. 
Price moving sideways (no uptrend) 
Insiders bought $4,842 (6M) 
Fair value $1.67 · Overvalued 
Quality 36/100 
Weak Growth (revenue 5y −11.9 %/yr in USD) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 5/100
Thin data 
Estimate
Watch Veru Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$237.80 $2.06 Fair Value $1.67 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $2.06 – $237.80 · fair‑value band $1.25 – $2.09 · the $2.08 price screens above the $1.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 17, 2026.

Follow Veru in your weekly email

Every Wednesday you see whether Veru is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.

Show moreShow less

It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.

The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Stock analysis

Veru Inc (VERU) currently trades at $2.08, while our estimate is $1.67, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.25 (bear) to $2.09 (bull), the price of $2.08 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Veru Inc reported revenue of $0 in FY2025 versus $61.3M in FY2021. Reported net income was −$22.7M in FY2025.

Key figures

Market cap $47.9M Micro · P/S ratio 2.25 · EPS (TTM) $−0.6100 · Return on equity −64.5% · Return on assets (EBIT) −77.1% (5-year average) · Revenue (TTM) $16.9M · Revenue growth (YoY) +18.3% · Free cash flow −$30.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 51% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, VERU screens richer than that median.

Fair Value

Bear $1.25 Fair Value $1.67 Bull $2.09
Price $2.08 · Downside -19.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $4,842, on Aug 13, 2026.

  • BuyK Gary BarnetteChief Scientific Officer1,800 shares at $2.69$4,842Aug 13, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.9%
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−20.2% (2019) → −218.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VERU screens overvalued: fair value 20% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Veru Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −19.7% · Above median
Profitability
Return on assets −76.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 18.3% · Above median
Balance sheet
Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.62× · Pricier than median
P/S (12 months) 2.84× · Cheapest 25%
PEG 3.60× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 1
FUTURE (revenue growth)92 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)76 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs VERU
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs VERU
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs VERU
argenx SE ARGX $950.95 $908.40 −4% vs VERU
CSL Limited CSL A$199.55 A$186.49 −7% vs VERU
Moderna, Inc MRNA $215.27 $135.64 −37% vs VERU
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs VERU
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs VERU
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs VERU
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs VERU

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Veru Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Veru Inc Fair Value". https://www.fairvalue-calculator.com/stock/VERU

Frequently asked questions

Is Veru Inc (VERU) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $1.67 versus a price of $2.08, about 20% lower (overvalued).
What is the fair value of VERU?
Our estimate for Veru Inc is $1.67 (as of Nov 17, 2026), built from audited fundamentals. The current price: $2.08.
What is the quality score of VERU?
Veru Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Veru Inc (VERU)?
Our calculated price target is the estimate of $1.67 (as of Nov 17, 2026). Cautious scenario $1.25, optimistic scenario $2.09. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Veru Inc stock forecast for 2026?
Our estimate puts fair value at $1.67, about 20% lower versus a price of $2.08 (overvalued). Cautious scenario $1.25, optimistic scenario $2.09. The calculation is refreshed regularly with new filings.
What is the revenue of Veru Inc (VERU)?
Veru Inc reported trailing-twelve-month revenue of about $16.9M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Veru Inc (VERU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Veru Inc it is $1.67 per share (as of Nov 17, 2026), against a price of $2.08.
Is Veru Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, VERU trades above its calculated fair value: price $2.08, fair value $1.67, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VERU?
No. The price is what the market pays today ($2.08); the fair value is what the company's own numbers justify ($1.67). For Veru Inc the two are $0.4100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Veru Inc worth?
The market values Veru Inc at about $47.9M (market capitalisation, as of Nov 17, 2026). Per share that is $2.08; our models calculate a fair value of $1.67 per share.
What do the bullish and bearish scenarios say about VERU?
Our models span a range for Veru Inc: cautious scenario $1.25, base $1.67, optimistic $2.09 per share (as of Nov 17, 2026, price $2.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of VERU?
The PEG ratio of Veru Inc is 3.60 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Veru Inc (VERU)?
Balance-sheet figures for Veru Inc (as of Nov 17, 2026): return on equity −64.5%, debt of 0.48 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is VERU from its 52-week high?
Veru Inc trades at $2.08, about 51% below its 52-week high of $4.23 and 1% above the low of $2.06 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.67 is for.
Which stocks are comparable to Veru Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Veru Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $2.08, calculated fair value $1.67 (−20%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Veru Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Veru Inc (VERU)?
The closing price on Nov 16, 2026 was $2.08. Our estimate is $1.67, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Veru Inc right now?
Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Veru Inc

How large is the market capitalisation of Veru Inc (VERU)?
The market capitalisation of Veru Inc is $47.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Veru Inc (VERU)?
The price-to-sales ratio of Veru Inc is 2.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Veru Inc (VERU)?
Earnings per share at Veru Inc are $−0.6100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Veru Inc (VERU)?
The return on equity (ROE) of Veru Inc is −64.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Veru Inc (VERU)?
On an EBIT basis the return on assets of Veru Inc is −77.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Veru Inc (VERU)?
Revenue at Veru Inc is growing 18.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Veru Inc (VERU) generate?
The free cash flow of Veru Inc is −$30.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Veru Inc (VERU) hold?
Veru Inc holds more cash than debt, $21.2M net (balance sheet 30 Jun 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Veru Inc in the live analysis

One click puts Veru Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.